We use cookies for a better user experience. Read our Privacy Policy

I Agree

Hepatorenal Syndrome Treatment Market

Hepatorenal Syndrome Treatment Market (Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome; Treatment: Therapeutics, Surgical Treatment; End User: Hospitals & Clinics, Ambulatory Surgical Centers, Academic & Research Institutes, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Exponential Growth in Therapeutics Boosts Growth of Hepatorenal Syndrome Treatment Market

Improvements in the therapeutics landscape of the hepatorenal syndrome treatment market are creating new avenues in incremental opportunities for healthcare companies. Although surgical treatments dominate the hepatorenal syndrome (HRS) treatment market, analysts at Transparency Market Research (TMR) anticipate an exponential growth for therapeutics in terms of market value share. Therapeutics are projected to rise from a market value share of ~1% in 2018 to ~6% by the end of 2027, in the hepatorenal syndrome treatment market. Thus, lucrative opportunities in the therapeutics landscape are attracting the attention of healthcare companies.

Healthcare companies are developing improved formulations of therapeutic drugs that are safe and effective for HRS patients. For instance, in May 2019, Mallinckrodt - a global specialty pharmaceutical company, announced the launch of Terlipressin - an investigational agent for the treatment of type 1 hepatorenal syndrome.

Since there are no treatments approved in the U.S. and Canada for HRS-1, healthcare companies are increasing their research efforts to reach full potential in terms of the enrollment of participants. Thus, active enrollment of participants in clinical studies will help enhance the credibility of research outcomes in the hepatorenal syndrome treatment market.

hepatorenal syndrome treatment market infographic

To know the scope of our report Get a Sample on Hepatorenal Syndrome Treatment Market   

Health Commissions Recommend Albumin as Cost-effective Treatment Option for Cirrhosis and HRS

Complications of cirrhosis lead to HRS and progressive kidney failure amongst patients with severe liver damage. Hence, healthcare providers prescribe albumin to cirrhotic patients with acute decompensation. Albumin is gaining increased popularity in the hepatorenal syndrome treatment market, since it serves as a cost-effective treatment option for HRS and cirrhosis. As such, there is growing demand for albumin in hospitals and ambulatory surgical centers across Germany, Italy, and Spain.

Get a glimpse of the in-depth analysis through our Report Brochure

Healthcare companies in the hepatorenal syndrome treatment market are increasing their production capabilities of albumin, since the protein serves as a low-cost and effective alternative to saline, gelatin, and no fluid treatment of large volume paracentesis (LVP). It is found that, the combination of albumin with antibiotics is clinically more effective than antibiotics alone in the hepatorenal syndrome treatment landscape. To reduce the severe complications of cirrhosis amongst HRS patients, healthcare companies in the hepatorenal syndrome treatment market are increasing awareness about the combination therapy of albumin with vasoconstrictors.

Albumin is being increasingly used in combination with other drugs such as terlipressin. This trend is gaining increased popularity due to its low medical complication costs. Due to reduced rates of renal impairment and reduced mortality rates, health commissions across various countries are recommending the prescription of albumin to treat serious conditions of HRS.

Economic Evaluation Helps Companies Analyze Cost Difference for HRS Treatment Options

HRS is characterized by renal failure in patients suffering from advanced chronic liver disease (CLD). This disease condition has led to increased hospitalizations in the U.S. As such, the U.S. currently accounts for the highest revenue amongst all regions in the hepatorenal syndrome treatment market, with a value recorded at ~US$ 5 billion in 2018. Therefore, companies in the hepatorenal syndrome treatment market are increasing their efforts to introduce advanced treatment options for HRS patients in the U.S. However, it is found that, there is a growing need for cost-efficient treatment alternatives for the diagnosis of HRS in the U.S. Costly HRS treatments have created the problem of economic burden amongst patients. This has adversely affected the credibility of outcomes, as patients lack access to cost-efficient and effective treatment options.

Hence, companies in the hepatorenal syndrome treatment market are carrying out extensive research to analyze the number of hospitals that offer treatments at a higher cost. This is particularly compared with hospitals in the developing countries of Asia Pacific. For instance, it has been found that, the cost of treatment for HRS is less expensive in India as compared to the economic evaluation of treatment offered in Brazil. Companies in the hepatorenal syndrome treatment market are increasing research & development to devise strategies that reduce the economic burden on patients, and are increasing the availability of effective treatment options at U.S. hospitals.

hepatorenal syndrome treatment market segmentation
Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

In 2027, surgical treatments are projected to account for ~94% market share of the hepatorenal syndrome treatment market. Hence, healthcare companies should focus on the application of evidence-based algorithms, catering to surgical and pharmacological options for patients suffering from HRS.

However, surgical repair of umbilical hernia in cirrhotic patients has increased risks of high postoperative morbidity and mortality. To overcome this hurdle, companies should aid healthcare providers to increase their efficacy in elective surgery with perioperative preparations to ensure effective and safe outcomes after a surgery. Since HRS treatment is less expensive in Asia Pacific, healthcare companies should capitalize on this opportunity, as the region is estimated for exponential market growth amongst all the other regions in the landscape.

Global Hepatorenal Syndrome Treatment Market: Overview

  • The global hepatorenal syndrome treatment market was valued at ~US$ 11 Bn in 2018 and is projected to reach a value of ~US$ 16.7 Bn by 2027, expanding at a CAGR of ~5% from 2019 to 2027.
  • North America, Europe, and Asia Pacific were the major regional hepatorenal syndrome treatment markets in 2018. The hepatorenal syndrome treatment markets in North America and Asia Pacific are likely to expand at CAGRs of 5.1% and 4.8%, respectively, during the forecast period.
  • The global hepatorenal syndrome treatment market is projected to witness high growth, owing to promising effective therapies in the pipeline for addressing gaps in the treatment of hepatorenal syndrome.
  • Increase in the prevalence and incidence of hepatorenal syndrome and development and launch of various pipeline drugs for the treatment of hepatorenal syndrome in the near future are expected to drive the global HRS treatment market during the forecast period.

Global Hepatorenal Syndrome Treatment Market: Significant Growth Prospects in Developing Countries

  • Developing economies in Asia Pacific, Latin America, and Eastern Europe hold great opportunities for the hepatorenal syndrome treatment market, owing to their increasing population, coupled with rise in health care-related customer expenditure brought about by the rise in their economies.
  • Continuous technological advancements in surgical procedures for liver and kidney diseases with respect to higher efficacy and targeted therapeutic role have widened the scope for players present in the hepatorenal syndrome treatment market.
  • New drugs with combined features of reduced side-effects and higher efficacy have a significant potential for growth in the hepatorenal syndrome treatment market. Thus, the introduction of new products can help new entrants establish their foothold in the hepatorenal syndrome treatment market.

Increase in Disease Awareness & Patient Support Programs to Boost Hepatorenal Syndrome Treatment Market

  • In order to reduce mortality and morbidity rates, governments in developed and developing countries are conducting awareness campaigns to encourage people to go for the early diagnosis of kidney and liver diseases. This, in turn, is expected to increase awareness regarding hepatorenal syndrome diagnosis and treatment, thereby boosting the growth of the global hepatorenal syndrome treatment market.
  • For instance, every 2nd Thursday of March is observed as World Kidney Day. It is a global awareness campaign to increase awareness about chronic kidney diseases and the introduction of healthy changes in life to reduce risk factors.
  • Moreover, in developing countries such as India, hospitals are raising awareness about these diseases. For instance, in February 2016, Noida-based Jaypee Hospital in India organized a kidney and liver disease awareness campaign.

Global Hepatorenal Syndrome Treatment Market: Fast Track and Orphan Drug Designations

  • In 1983, recognizing that adequate drugs for rare disorders had not been developed in the U.S., the Congress passed the Orphan Drug Act to provide incentives to induce companies to develop drugs for THE treatment of rare and neglected diseases. Orphan drug status is granted to drugs and biologics that are intended for the diagnosis, prevention, or treatment of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Orphan drugs are given priority review, allowing them to be assessed within six months for approval.
  • Hepatorenal syndrome is a form of impaired kidney function that occurs in individuals with advanced chronic liver disease. AROUND 40% of people with ascites and cirrhosis develop hepatorenal syndrome.
  • In case of hepatorenal syndrome treatment, several drugs have received orphan drug designation, thereby accelerating their approval process, and this can act as a factor pushing the growth of the hepatorenal syndrome treatment market.
  • For instance, in November 2004, ESP Pharma, Inc. announced that FDA had granted Orphan Drug Designation to Terlipressin for the treatment of hepatorenal syndrome Type 1, providing seven years marketing exclusivity upon the completion of clinical studies and FDA approval of the drug for this indication.
  • Additionally, in November 2018, BioVie Inc. announced that the FDA has granted Orphan Drug designation to its Terlipressin drug for the treatment of hepatorenal syndrome (HRS).
  • The designation for orphan drug allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials, along with seven years of market exclusivity upon regulatory approval. This is likely to drive the hepatorenal syndrome treatment market during the forecast period.

Global Hepatorenal Syndrome Treatment Market: Competition Landscape

  • Strategic collaborations among key manufacturers and companies having their products in clinical trials to expedite the process of research & development are likely to help thousands of patients suffering from hepatorenal syndrome. Rise in the trend of collaborations is projected to drive the hepatorenal syndrome treatment market by fueling novel product launches.
  • In 2010, Ikaria, Inc. entered into a strategic collaboration with Orphan Therapeutics to acquire the rights of Orphan Therapeutics’ drug ‘LUCASSIN’ in North America and Australia. Ikaria, Inc. holds all the necessary rights to manufacture, develop, and commercialize LUCASSIN in Mexico, the U.S., and Australia.
  • Additionally, in April 2017, Mallinckrodt plc acquired Ikaria, Inc. The deal was valued at US$ 2.3 Bn.
  • Such collaborations are likely to enhance the chances of the development of comprehensive treatment for hepatorenal syndrome, thereby improving the survival rate of patients, and eventually surging the growth of the hepatorenal syndrome treatment market.

Hepatorenal Syndrome Treatment Market - Segmentation

In order to understand the granular and broader nuances of the market, the segmentation of the hepatorenal syndrome treatment market has been done on the basis of type, treatment, end user, and region. This is one way by which incremental opportunities can be assessed in the hepatorenal syndrome treatment market.

Type

Type 1

Hepatorenal

Syndrome

Type 2

Hepatorenal

Syndrome

Treatment

Therapeutics

  • Terlivaz
  • Glypressin
  • Lucassin
  • Hepatoren

Surgical Treatment

  • Liver Transplantation
  • Surgical Shunting
  • Renal Replacement Therapy
  • Others

End User

Hospitals &

Clinics

Ambulatory

Surgical

Centers

Academic &

Research

Institutes

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of hepatorenal syndrome treatment market?

Hepatorenal syndrome treatment market to reach a valuation of ~US$ 16.7 Bn by 2027

What is the anticipated CAGR of the hepatorenal syndrome treatment market in the forecast period?

Hepatorenal syndrome treatment market is projected to expand at a CAGR of ~5% from 2019 to 2027

What are the key driving factors for the growth of the hepatorenal syndrome treatment market?

Hepatorenal syndrome treatment market is driven by an increase in the awareness and acceptance of hepatorenal syndrome treatment

Which region is expected to project the highest market share in the global hepatorenal syndrome treatment market?

North America accounted for a major share of the global hepatorenal syndrome treatment market

Who are the key players in the global hepatorenal syndrome treatment market?

Key players in the global hepatorenal syndrome treatment market include Cumberland Pharmaceuticals, Inc., Orphan Therapeutics, LLC, BioVie Inc., and Mallinckrodt Pharmaceuticals.

1. Preface 

    1.1. Report Scope and Market Segmentation 

    1.2. Research Highlights

2. Assumptions and Research Methodology 

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

    3.1. Global Hepatorenal Syndrome Treatment Market: Market Snapshot

4. Market Overview

    4.1. Global Hepatorenal Syndrome Treatment Market: Type Overview 

    4.2. Global Hepatorenal Syndrome Treatment Market: Key Industry Developments

    4.3. Market Dynamics

    4.4. Drivers and Restraints Snapshot Analysis

    4.5. Drivers

        4.5.1. Fast track and orphan drug designations

        4.5.2. Increase in strategic collaboration among key players

    4.6. Restraints

        4.6.1. Side-effects and risks related to drug usage

        4.6.2. Stringent regulatory requirements

    4.7. Opportunities

    4.8. Global Hepatorenal Syndrome Treatment Market Revenue Projections (US$ Mn), 2017–2027

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Regulatory Scenario by Region/Country

    5.3. Key Industry Events (Mergers, Acquisitions, Collaborations, Launch & Approvals, etc)

    5.4. Prevalence of Liver & Kidney Diseases by Region/Globally

6. Global Hepatorenal Syndrome Treatment Market Analysis, by Type

    6.1. Introduction

    6.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        6.2.1. Type 1 Hepatorenal Syndrome

        6.2.2. Type 2 Hepatorenal Syndrome

    6.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Type

    6.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Type

7. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment

    7.1. Introduction

    7.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        7.2.1. Therapeutics

            7.2.1.1. Terlivaz

            7.2.1.2. Glypressin

            7.2.1.3. Lucassin 

            7.2.1.4. Hepatoren

        7.2.2. Surgical Treatment

            7.2.2.1. Liver Transplantation

            7.2.2.2. Surgical Shunting

                7.2.2.2.1. Peritoneovenous Shunting

                7.2.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                7.2.2.2.3. Others

            7.2.2.3. Renal Replacement Therapy

            7.2.2.4. Others

    7.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment

    7.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Treatment

8. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user

    8.1. Introduction

    8.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        8.2.1. Hospitals & Clinics

        8.2.2. Ambulatory Surgical Centers

        8.2.3. Academic & Research Institutes

        8.2.4. Others

    8.3. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user

    8.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by End-user

9. Global Hepatorenal Syndrome Treatment Market Analysis, by Region

    9.1. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Region, 2017–2027 

        9.1.1. North America

        9.1.2. Europe

        9.1.3. Asia Pacific

        9.1.4. Latin America

        9.1.5. Middle East & Africa

    9.2. Global Hepatorenal Syndrome Treatment Market Analysis, by Region

    9.3. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Region

10. North America Hepatorenal Syndrome Treatment Market Analysis

    10.1. North America Hepatorenal Syndrome Treatment Market 

    10.2. North America Hepatorenal Syndrome Treatment Market Overview

    10.3. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        10.3.1. Type 1 Hepatorenal Syndrome

        10.3.2. Type 2 Hepatorenal Syndrome

    10.4. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        10.4.1. Therapeutics

            10.4.1.1. Terlivaz

            10.4.1.2. Glypressin

            10.4.1.3. Lucassin 

            10.4.1.4. Hepatoren

        10.4.2. Surgical Treatment

            10.4.2.1. Liver Transplantation

            10.4.2.2. Surgical Shunting

                10.4.2.2.1. Peritoneovenous Shunting

                10.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                10.4.2.2.3. Others

            10.4.2.3. Renal Replacement Therapy

        10.4.3. Others

    10.5. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        10.5.1. Hospitals & Clinics

        10.5.2. Ambulatory Surgical Centers

        10.5.3. Academic & Research Institutes

        10.5.4. Others

    10.6. North America Hepatorenal Syndrome Treatment Market Forecast, by Country

        10.6.1. U.S.

        10.6.2. Canada

    10.7. North America Hepatorenal Syndrome Treatment Market Attractiveness Analysis 

        10.7.1. By Type

        10.7.2. By Treatment

        10.7.3. By End-user

        10.7.4. By Country

11. Europe Hepatorenal Syndrome Treatment Market Analysis

    11.1. Europe Hepatorenal Syndrome Treatment Market 

    11.2. Europe Hepatorenal Syndrome Treatment Market Overview

    11.3. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        11.3.1. Type 1 Hepatorenal Syndrome

        11.3.2. Type 2 Hepatorenal Syndrome

    11.4. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        11.4.1. Therapeutics

            11.4.1.1. Terlivaz

            11.4.1.2. Glypressin

            11.4.1.3. Lucassin 

            11.4.1.4. Hepatoren

        11.4.2. Surgical Treatment

            11.4.2.1. Liver Transplantation

            11.4.2.2. Surgical Shunting

                11.4.2.2.1. Peritoneovenous Shunting

                11.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                11.4.2.2.3. Others

            11.4.2.3. Renal Replacement Therapy

        11.4.3. Others

    11.5. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        11.5.1. Hospitals & Clinics

        11.5.2. Ambulatory Surgical Centers

        11.5.3. Academic & Research Institutes

        11.5.4. Others

    11.6. Europe Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

        11.6.1. U.K.

        11.6.2. France

        11.6.3. Germany

        11.6.4. Spain

        11.6.5. Italy

        11.6.6. Rest of Europe

    11.7. Europe Hepatorenal Syndrome Treatment Market Attractiveness Analysis 

        11.7.1. By Type

        11.7.2. By Treatment

        11.7.3. By End-user

        11.7.4. By Country/Sub-region

12. Asia Pacific Hepatorenal Syndrome Treatment Market Analysis

    12.1. Asia Pacific Hepatorenal Syndrome Treatment Market Key Findings

    12.2. Asia Pacific Hepatorenal Syndrome Treatment Market Overview

    12.3. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        12.3.1. Type 1 Hepatorenal Syndrome

        12.3.2. Type 2 Hepatorenal Syndrome

    12.4. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        12.4.1. Therapeutics

            12.4.1.1. Terlivaz

            12.4.1.2. Glypressin

            12.4.1.3. Lucassin 

            12.4.1.4. Hepatoren

        12.4.2. Surgical Treatment

            12.4.2.1. Liver Transplantation

            12.4.2.2. Surgical Shunting

                12.4.2.2.1. Peritoneovenous Shunting

                12.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                12.4.2.2.3. Others

            12.4.2.3. Renal Replacement Therapy

        12.4.3. Others

    12.5. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        12.5.1. Hospitals & Clinics

        12.5.2. Ambulatory Surgical Centers

        12.5.3. Academic & Research Institutes

        12.5.4. Others

    12.6. Asia Pacific Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

        12.6.1. China

        12.6.2. India

        12.6.3. Japan

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7. Asia Pacific Hepatorenal Syndrome Treatment Market Attractiveness Analysis 

        12.7.1. By Type

        12.7.2. By Treatment

        12.7.3. By End-user

        12.7.4. By Country/Sub-region

13. Latin America Hepatorenal Syndrome Treatment Market Analysis

    13.1. Latin America Hepatorenal Syndrome Treatment Market Key Findings

    13.2. Latin America Hepatorenal Syndrome Treatment Market Overview

    13.3. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        13.3.1. Type 1 Hepatorenal Syndrome

        13.3.2. Type 2 Hepatorenal Syndrome

    13.4. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        13.4.1. Therapeutics

            13.4.1.1. Terlivaz

            13.4.1.2. Glypressin

            13.4.1.3. Lucassin 

            13.4.1.4. Hepatoren

        13.4.2. Surgical Treatment

            13.4.2.1. Liver Transplantation

            13.4.2.2. Surgical Shunting

                13.4.2.2.1. Peritoneovenous Shunting

                13.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                13.4.2.2.3. Others

            13.4.2.3. Renal Replacement Therapy

        13.4.3. Others

    13.5. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        13.5.1. Hospitals & Clinics

        13.5.2. Ambulatory Surgical Centers

        13.5.3. Academic & Research Institutes

        13.5.4. Others

    13.6. Latin America Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7. Latin America Hepatorenal Syndrome Treatment Market Attractiveness Analysis 

        13.7.1. By Type

        13.7.2. By Treatment

        13.7.3. By End-user

        13.7.4. By Country/Sub-region

14. Middle East & Africa Hepatorenal Syndrome Treatment Market Analysis

    14.1. Middle East & Africa Hepatorenal Syndrome Treatment Market 

    14.2. Middle East & Africa Hepatorenal Syndrome Treatment Market Overview

    14.3. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by Type

        14.3.1. Type 1 Hepatorenal Syndrome

        14.3.2. Type 2 Hepatorenal Syndrome

    14.4. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment

        14.4.1. Therapeutics

            14.4.1.1. Terlivaz

            14.4.1.2. Glypressin

            14.4.1.3. Lucassin 

            14.4.1.4. Hepatoren

        14.4.2. Surgical Treatment

            14.4.2.1. Liver Transplantation

            14.4.2.2. Surgical Shunting

                14.4.2.2.1. Peritoneovenous Shunting

                14.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)

                14.4.2.2.3. Others

            14.4.2.3. Renal Replacement Therapy

        14.4.3. Others

    14.5. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user

        14.5.1. Hospitals & Clinics

        14.5.2. Ambulatory Surgical Centers

        14.5.3. Academic & Research Institutes

        14.5.4. Others

    14.6. Middle East & Africa Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region

        14.6.1. GCC Countries

        14.6.2. South Africa

        14.6.3. Rest of Middle East & Africa

    14.7. Middle East & Africa Hepatorenal Syndrome Treatment Market Attractiveness Analysis 

        14.7.1. By Type

        14.7.2. By Treatment

        14.7.3. By End-user

        14.7.4. By Country/Sub-region

15. Competitive Landscape 

    15.1. Company Profiles

        15.1.1. Cumberland Pharmaceuticals, Inc.

            15.1.1.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.1.2. Financials

            15.1.1.3. Recent Developments

            15.1.1.4. Strategy

        15.1.2. Orphan Therapeutics, LLC. 

            15.1.2.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.2.2. Financials

            15.1.2.3. Recent Developments

            15.1.2.4. Strategy

        15.1.3. BioVie Inc.

            15.1.3.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.3.2. Financials

            15.1.3.3. Recent Developments

            15.1.3.4. Strategy

        15.1.4. Mallinckrodt Pharmaceuticals 

            15.1.4.1. Overview (HQ, Employee Strength, Business Segments)

            15.1.4.2. Financials

            15.1.4.3. Recent Developments

            15.1.4.4. Strategy

List of Tables

TABLE 1 Global Hepatorenal Syndrome Treatment Pipeline Analysis (1/5)

TABLE 2 Global Hepatorenal Syndrome Treatment Pipeline Analysis (2/5)

TABLE 3 Global Hepatorenal Syndrome Treatment Pipeline Analysis (3/5)

TABLE 4 Global Hepatorenal Syndrome Treatment Pipeline Analysis (4/5)

TABLE 5 Global Hepatorenal Syndrome Treatment Pipeline Analysis (5/5)

TABLE 6 Comparative Analysis of Orphan Drug Policies

TABLE 7 Worldwide Epidemiology of Liver Diseases 

TABLE 8 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 9 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 10 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 11 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 12 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 13 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 14 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

TABLE 15 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

TABLE 16 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 17 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 18 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 19 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 20 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 21 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 22 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 23 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 24 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 25 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 26 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 27 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 28 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 29 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 30 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 31 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 32 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 33 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 34 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 35 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 36 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 37 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 38 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 39 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 40 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 41 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 42 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

TABLE 43 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 44 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027

TABLE 45 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027

TABLE 46 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027

TABLE 47 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027

TABLE 48 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027

TABLE 49 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

List of Figures

FIG. 1 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027

FIG. 2 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Type (2018)

FIG. 3 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Treatment (2018)

FIG. 4 Global Hepatorenal Syndrome Treatment Market Value Share (%), by End-user (2018)

FIG. 5 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Region (2018)

FIG. 6 Regulatory Approval Process - U.S.  

FIG. 7 Regulatory Approval Process - Europe 

FIG. 8 Regulatory Approval Process - Japan

FIG. 9 Regulatory Approval Process - China

FIG. 10 Revision of Drug Administration Law & Drug Registration Regulation

FIG. 11 Drug Approval Process in China - Step 1

FIG. 12 Drug Approval Process in China - Step 2

FIG. 13 Drug Approval Process in China - Step 3

FIG. 14 Recent CFDA Regulatory Reforms to Support Innovative Drugs

FIG. 15 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Type, 2018 and 2027

FIG. 16 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Type, 2019–2027

FIG. 17 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Type 1 Hepatorenal Syndrome, 2017–2027

FIG. 18 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Type 2 Hepatorenal Syndrome, 2017–2027

FIG. 19 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Treatment, 2018 and 2027

FIG. 20 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Treatment, 2019–2027

FIG. 21 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Therapeutics, 2017–2027

FIG. 22 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Surgical Treatment, 2017–2027

FIG. 23 Global Hepatorenal Syndrome Treatment Market Value Share (%), by End-user, 2018 and 2027

FIG. 24 Global Hepatorenal Syndrome Treatment Market Attractiveness, by End-user, 2019–2027

FIG. 25 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals & Clinics, 2017–2027

FIG. 26 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgical Centers, 2017–2027

FIG. 27 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Academic & Research Institutes, 2017–2027

FIG. 28 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027

FIG. 29 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Region, 2018 and 2027

FIG. 30 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Region, 2019–2027

FIG. 31 North America Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 32 North America Hepatorenal Syndrome Treatment Market Value Share (%), by Country, 2018 and 2027

FIG. 33 North America Hepatorenal Syndrome Treatment Market Attractiveness, by Country, 2019–2027

FIG. 34 Europe Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 35 Europe Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 36 Europe Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 37 Asia Pacific Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 38 Asia Pacific Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 39 Asia Pacific Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 40 Latin America Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 41 Latin America Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 42 Latin America Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 43 Middle East & Africa Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

FIG. 44 Middle East & Africa Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027

FIG. 45 Middle East & Africa Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

FIG. 46 Cumberland Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

FIG. 47 Cumberland Pharmaceuticals, Inc., Breakdown of Net Sales, by Region, 2018

FIG. 48 Mallinckrodt Pharmaceuticals, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

FIG. 49 Mallinckrodt Pharmaceuticals, R&D Expenses, 2015–2018

FIG. 50 Mallinckrodt Pharmaceuticals, Breakdown of Net Sales, by Region, 2018

FIG. 51 Mallinckrodt Pharmaceuticals, Breakdown of Net Sales, by Business Segment, 2018

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

463

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved